Phesi selected as finalist for 2018 scrip award

Date: 10. 10. 2018

(BUSINESS WIRE) October 10, 2018

EAST LYME, Conn. Phesi, a technology-enabled, data-driven provider of premier clinical development services, today announced it is a finalist for a 2018 Scrip Award, one of the pharmaceutical and biotech industries’ most prestigious honors. The company has been selected as one of six finalists in the Best Technological Development in Clinical Trials – Tech Sponsor-focused category, which “recognize[s] the promising and disruptive role that digital health technology now plays in clinical drug development,” according to the Scrip Awards 2018 website.

Read the full press release at Business Wire.

Related news
06. 10. 2024
Global oncology trial investigator sites increase by half in five years, finds new Phesi analysis Read more
05. 14. 2024
Phesi launches predictive Patient Burden Score to improve trial efficiency, patient experience and investigator site performance Read more
05. 08. 2024
Phesi Q1 2024 Business Update Read more
02. 12. 2024
Phesi announces AI-driven Trial Accelerator™ hits critical milestone with data from 100 million patients Read more
01. 16. 2024
Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year Read more
10. 15. 2023
Phesi launches Health Check and Trial Rescue Service to save at-risk trials and bring drugs to market faster Read more